Cross-resistance to clinically used tyrosine kinase inhibitors sunitinib, sorafenib and pazopanib

K.J. Gotink, M.N. Rovithi, R.R. de Haas, R.J. Honeywell, H. Dekker, D. Poel, K. Azijli, G.J. Peters, H.J. Broxterman, H.M.W. Verheul

Research output: Contribution to journalArticleAcademicpeer-review

Original languageUndefined/Unknown
Pages (from-to)119-129
JournalCellular Oncology
Volume38
Issue number2
DOIs
Publication statusPublished - 2015

Cite this

@article{f7d20640ccbd4a4185229fbbfae86dc5,
title = "Cross-resistance to clinically used tyrosine kinase inhibitors sunitinib, sorafenib and pazopanib",
author = "K.J. Gotink and M.N. Rovithi and {de Haas}, R.R. and R.J. Honeywell and H. Dekker and D. Poel and K. Azijli and G.J. Peters and H.J. Broxterman and H.M.W. Verheul",
year = "2015",
doi = "10.1007/s13402-015-0218-8",
language = "Undefined/Unknown",
volume = "38",
pages = "119--129",
journal = "Cellular Oncology",
issn = "2211-3428",
publisher = "IOS Press",
number = "2",

}

Cross-resistance to clinically used tyrosine kinase inhibitors sunitinib, sorafenib and pazopanib. / Gotink, K.J.; Rovithi, M.N.; de Haas, R.R.; Honeywell, R.J.; Dekker, H.; Poel, D.; Azijli, K.; Peters, G.J.; Broxterman, H.J.; Verheul, H.M.W.

In: Cellular Oncology, Vol. 38, No. 2, 2015, p. 119-129.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Cross-resistance to clinically used tyrosine kinase inhibitors sunitinib, sorafenib and pazopanib

AU - Gotink, K.J.

AU - Rovithi, M.N.

AU - de Haas, R.R.

AU - Honeywell, R.J.

AU - Dekker, H.

AU - Poel, D.

AU - Azijli, K.

AU - Peters, G.J.

AU - Broxterman, H.J.

AU - Verheul, H.M.W.

PY - 2015

Y1 - 2015

U2 - 10.1007/s13402-015-0218-8

DO - 10.1007/s13402-015-0218-8

M3 - Article

VL - 38

SP - 119

EP - 129

JO - Cellular Oncology

JF - Cellular Oncology

SN - 2211-3428

IS - 2

ER -